Second-versus first-generation "limus"-eluting stents in diabetic patients with coronary artery disease: A randomized comparison in setting of ISAR-TEST-4 trial

Catheterization and Cardiovascular Interventions

Volumn 82, Issue 6, 2013, Pages

  Kufner, Sebastian ^a   Byrne, Robert A ^a   Mehilli, Julinda ^a   Massberg, Steffen ^a   Birkmeier, Katrin A ^a   Schulz, Stefanie ^a   Pache, Jürgen ^a   Schömig, Albert ^b   Kastrati, Adnan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

coronary artery disease; diabetes; percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; RAPAMYCIN; CARDIOVASCULAR AGENT;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DIABETES MELLITUS; DIABETIC PATIENT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; INCIDENCE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROBABILITY; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; RISK ASSESSMENT; STENT THROMBOSIS; ADVERSE EFFECTS; COMPARATIVE STUDY; COMPLICATION; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DEVICES; KAPLAN MEIER METHOD; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSTHESIS DESIGN; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

AGED; CARDIOVASCULAR AGENTS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY THROMBOSIS; DIABETES MELLITUS; DRUG-ELUTING STENTS; EVEROLIMUS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PROSTHESIS DESIGN; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84887312778     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.24741     Document Type: Article

References (21)

1. Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J, Neumann FJ, Schomig A,. Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998; 32: 1866-1873.
2. Jensen LO, Maeng M, Thayssen P, Kaltoft A, Tilsted HH, Lassen JF, Hansen KN, Bottcher M, Rasmussen K, Madsen M, Johnsen SP, Sorensen HT, Thuesen L,. Long-term outcomes after percutaneous coronary intervention in patients with and without diabetes mellitus in Western Denmark. Am J Cardiol 2010; 105: 1513-1519.
3. Barry A, Wilkinson I, Halford V, Springett K, McInnes A,. A clinical study and the national service framework for diabetes. J Tissue Viability 2004; 14: 124, 126, 128, passim.
4. Byrne RA, Kastrati A, Kufner S, Massberg S, Birkmeier KA, Laugwitz KL, Schulz S, Pache J, Fusaro M, Seyfarth M, Schomig A, Mehilli J,. Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: The Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial. Eur Heart J 2009; 30: 2441-2449.
5. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM, Seixas AC, Staico R, Mattos LA, Sousa AG, Falotico R, Jaeger J, Popma JJ, Serruys PW,. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: A quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 2001; 103: 192-195.
6. Kukreja N, Onuma Y, Serruys PW,. Xience V everolimus-eluting coronary stent. Expert Rev Med Devices 2009; 6: 219-229.
7. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW,. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344-2351.
8. FDA. Guidance for Industry. Coronary Drug-Eluting Stents-Nonclinical and Clinical Studies. Silver Spring, MD: FDA; March 2008.
9. Patterson C, Mapera S, Li HH, Madamanchi N, Hilliard E, Lineberger R, Herrmann R, Charles P,. Comparative effects of paclitaxel and rapamycin on smooth muscle migration and survival: Role of AKT-dependent signaling. Arterioscler Thromb Vasc Biol 2006; 26: 1473-1480.
10. de Waha A, Dibra A, Kufner S, Baumgart D, Sabate M, Maresta A, Schomig A, Kastrati A,. Long-term outcome after sirolimus-eluting stents versus bare metal stents in patients with diabetes mellitus: A patient-level meta-analysis of randomized trials. Clin Res Cardiol 2011; 100: 561-570.
11. Kufner S, de Waha A, Tomai F, Park SW, Lee SW, Lim DS, Kim MH, Galloe AM, Maeng M, Briguori C, Dibra A, Schomig A, Kastrati A,. A meta-analysis of specifically designed randomized trials of sirolimus-eluting versus paclitaxel-eluting stents in diabetic patients with coronary artery disease. Am Heart J. 2011; 162: 740-747.
12. Kereiakes DJ, Cutlip DE, Applegate RJ, Wang J, Yaqub M, Sood P, Su X, Su G, Farhat N, Rizvi A, Simonton CA, Sudhir K, Stone GW,. Outcomes in diabetic and nondiabetic patients treated with everolimus- or paclitaxel-eluting stents: results from the SPIRIT IV clinical trial (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System). J Am Coll Cardiol 2010; 56: 2084-2089.
13. Stone GW, Kedhi E, Kereiakes DJ, Parise H, Fahy M, Serruys PW, Smits PC,. Differential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation 2011; 124: 893-900.
14. Kim WJ, Lee SW, Park SW, Kim YH, Yun SC, Lee JY, Park DW, Kang SJ, Lee CW, Lee JH, Choi SW, Seong IW, Lee BK, Lee NH, Cho YH, Shin WY, Lee SJ, Hyon MS, Bang DW, Park WJ, Kim HS, Chae JK, Lee K, Park HK, Park CB, Lee SG, Kim MK, Park KH, Choi YJ, Cheong SS, Yang TH, Jang JS, Her SH, Park SJ,. Randomized comparison of everolimus-eluting stent versus sirolimus-eluting stent implantation for de novo coronary artery disease in patients with diabetes mellitus (ESSENCE-DIABETES): Results from the ESSENCE-DIABETES trial. Circulation 2011; 124: 886-892.
15. Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, von Beckerath N, Ulm K, Wessely R, Dirschinger J, Schomig A,. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients. N Engl J Med 2005; 353: 663-670.
16. Kim MH, Hong SJ, Cha KS, Park HS, Chae SC, Hur SH, Gwon HC, Bae JH, Lim DS,. Effect of paclitaxel-eluting versus sirolimus-eluting stents on coronary restenosis in Korean diabetic patients. J Interv Cardiol 2008; 21: 225-231.
17. Lee SW, Park SW, Kim YH, Yun SC, Park DW, Lee CW, Hong MK, Rhee KS, Chae JK, Ko JK, Park JH, Lee JH, Choi SW, Jeong JO, Seong IW, Cho YH, Lee NH, Kim JH, Chun KJ, Kim HS, Park SJ,. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus. J Am CollCardiol 2008; 52: 727-733.
18. Maeng M, Jensen LO, Galloe AM, Thayssen P, Christiansen EH, Hansen KN, Helqvist S, Botker HE, Lassen JF, Thuesen L,. Comparison of the sirolimus-eluting versus paclitaxel-eluting coronary stent in patients with diabetes mellitus: The diabetes and drug-eluting stent (DiabeDES) randomized angiography trial. Am JCardiol 2009; 103: 345-349.
19. Tomai F, Reimers B, De Luca L, Galassi AR, Gaspardone A, Ghini AS, Ferrero V, Favero L, Gioffre G, Prati F, Tamburino C, Ribichini F,. Head-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: A prospective, randomized, multicenter study. Diabetes Care 2008; 31: 15-19.
20. Otake H, Honda Y, Courtney BK, Shimohama T, Ako J, Waseda K, Macours N, Rogers C, Popma JJ, Abizaid A, Ormiston JA, Spaulding C, Cohen SA, Fitzgerald PJ,. Intravascular ultrasound results from the NEVO ResElution-I trial: a randomized, blinded comparison of sirolimus-eluting NEVO stents with paclitaxel-eluting TAXUS Liberte stents in de novo native coronary artery lesions. Circ Cardiovasc Interv 2011; 4: 146-154.
21. Byrne RA, Kastrati A, Massberg S, Wieczorek A, Laugwitz K L, Hadamitzky M, Schulz S, Pache J, Fusaro M, Hausleiter J, Schomig A, Mehilli J,. Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial. J Am Coll Cardiol 2011; 58: 1325-1331.